Search clinical trials for: Dapagliflozin Placebo

Total 54453 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy Volunteers

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure (CHIEF-HF)

Heart Failure

United States
Université de Sherbrooke
Janssen Inc.

Withdrawn

Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF) (Canacardia)

Heart Failure | Type2 Diabetes
Yale University
AstraZeneca

Not yet recruiting

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy

Breast Cancer | Hyperinsulinism | HER2-negative Breast Cancer

United States
Johns Hopkins University
University of California, Los Angeles; AstraZeneca; Brett Boyer Foundation

Enrolling by invitation

The Fontan Dapagliflozin Pilot Study (FonDap)

Heart Failure

United States
Holbaek Sygehus

Enrolling by invitation

Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment (PRESERVE)

End Stage Renal Disease | Peritoneal Dialysis Complication

Denmark
George Clinical Pty Ltd
University Medical Center Groningen; Ground Zero Pharmaceuticals

Unknown

An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function

Diabetes Mellitus, Type 2 | Impaired Renal Function

Canada
Albert Einstein Healthcare Network

Suspended

Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury (DAPA-PCI-AKI)

Acute Kidney Injury | Percutaneous Coronary Intervention

United States
Novo Nordisk A/S

Completed

A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet

Healthy Volunteers

Germany
University of Campinas, Brazil

Completed

Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis Patients (DARE-ESKD 1)

End-stage Renal Disease

Brazil
Steno Diabetes Center Copenhagen
Novo Nordisk A/S; Glostrup University Hospital, Copenhagen

Completed

Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes (Astronaut)

Hypoxia | Type 1 Diabetes | Nephropathy | Autonomic Neuropathy, Diabetic | Mitochondrial Alteration

Denmark
Hamad Medical Corporation

Unknown

Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction

Myocardial Infarction | PreDiabetes | CVD | T2DM (Type 2 Diabetes Mellitus)

Qatar
Peter Rossing

Completed

Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes (DapKid)

Diabetic Nephropathy | Type 2 Diabetes

Denmark
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Healthy

United States
Mount Sinai Hospital, Canada
Boehringer Ingelheim

Recruiting

Empagliflozin and the Preservation of Beta-cell Function in Women With Recent Gestational Diabetes (EMPA post-GDM)

Gestational Diabetes

Canada
AstraZeneca
Bristol-Myers Squibb

Completed

Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects (ULDS)

Type 2 Diabetes

United States
Dong-A University

Recruiting

Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

Renal Insufficiency, Chronic | Percutaneous Coronary Intervention | Cardiac Catheterization

Korea, Republic of
RenJi Hospital

Recruiting

The Safety of Dapagliflozin in Hemodialysis Patients With Heart Failure (SDHF)

Hemodialysis Complication

China
Postgraduate Institute of Medical Education and...

Completed

Evaluation of Changes in Pancreatic Fat Content Using Advanced MR Sequences in Diabetics on Dapagliflozin Therapy

Pancreatic Lipomatosis

India
CHEOL WHAN LEE, M.D., Ph.D

Terminated

Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease

Coronary Artery Disease | Prediabetic State

Korea, Republic of
AstraZeneca
Bristol-Myers Squibb

Completed

Drug Interaction With Metformin

Healthy Male and Female Subjects

United States
AstraZeneca

Completed

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

Type 2 Diabetes Mellitus | Inadequate Glycaemic Control

United States, Canada, Czechia, Germany, Russian Federation, Mexico
AstraZeneca

Completed

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Type 2 Diabetes

United States, Hungary, Mexico, South Africa, Romania, Poland
AstraZeneca

Completed

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Type 2 Diabetes Mellitus, CKD and Albuminuria

United States, Spain, Canada, Korea, Republic of, Mexico, Japan, Taiwan, Australia, South Africa
Janssen Research & Development, LLC

Completed

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

United States
AstraZeneca

Completed

Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

Type 2 Diabetes Mellitus

United Kingdom
University Hospital Goettingen
German Research Foundation

Recruiting

Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients (DOUBLE_PROTECT)

Chronic Kidney Failure in Children and Young Adults

Germany
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Effect of Dapagliflozin on VT in Patients With Heart Failure.

Heart Failure
University of Sao Paulo General Hospital
Federal University of São Paulo

Recruiting

EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.

Diabetes Mellitus, Type 2 | Diabetes Complications | Kidney Transplantation

Brazil
The TIMI Study Group
AstraZeneca; Worldwide Clinical Trials

Recruiting

Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)

Heart Failure | Acute Heart Failure

United States
Tan Tock Seng Hospital

Withdrawn

Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease (DECODED)

Cardiovascular Diseases | End Stage Renal Disease
Mariëlle Scheffer
AstraZeneca

Unknown

Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction (STADIA-HFpEF)

Heart Failure, Diastolic

Netherlands
The Catholic University of Korea
AstraZeneca; Severance Hospital; Eulji General Hospital; Kyung Hee University Hospital...

Completed

Effect of Dapagliflozin on Glycemic Variability (DIVE)

Type 2 Diabetes Mellitus

Korea, Republic of
AstraZeneca
Bristol-Myers Squibb

Completed

Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes | High Blood Sugar

Japan
AstraZeneca
Bristol-Myers Squibb

Completed

Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin

Type 2 Diabetes

United States, Bulgaria, Russian Federation, United Kingdom, Hungary, Romania, Finland, Canada, Austria, Germany, Netherlands, Slovakia, Spain
AstraZeneca
Bristol-Myers Squibb

Completed

Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

Japan
AstraZeneca
Bristol-Myers Squibb

Suspended

Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone

Type 2 Diabetes

India
Boehringer Ingelheim

Completed

Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets

Healthy

Canada
Medical University of Graz
Medical University of Vienna; Johannes Kepler University of Linz; Paracelsus... and other collaborators

Completed

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction (EMMY)

Acute Myocardial Infarction

Austria
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

Healthy

United States
University of Oxford
Oxford Brookes University; The Leona M. and Harry B. Helmsley Charitable Trust

Terminated

Dapagliflozin During Exercise for the PrevenTion of Hypoglycaemia (DEPTH)

Diabetes Mellitus, Type 1

United Kingdom
Tanta University

Active, not recruiting

Empagliflozin in Treatment of Peripheral Diabetic Neuropathy

Diabetic Neuropathy Peripheral

Egypt
AstraZeneca
Bristol-Myers Squibb

Completed

A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets

Healthy Volunteers

Germany
Ann & Robert H Lurie Children's Hospital of Chicago

Not yet recruiting

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease (SLIDE)

NAFLD | Non-Alcoholic Fatty Liver Disease | Pediatric NAFLD

United States
Ottawa Heart Institute Research Corporation

Not yet recruiting

Dapagliflozin in STEMI Randomized Clinical Trial (DAPA STEMI)

Myocardial Infarction | ST Elevation Myocardial Infarction

Canada
Northwestern University
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Recruiting

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

Heart Failure | Kidney Diseases | Chronic Kidney Diseases | Heart Failure With Preserved Ejection Fraction

United States
Chang Gung Memorial Hospital

Active, not recruiting

Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation

Catheter Ablation | Atrial Fibrillation Recurrent

Taiwan
AstraZeneca
Bristol-Myers Squibb

Completed

Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers

Healthy

Sweden
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

Healthy

United States

3

Subscribe